Rechercher des projets européens

Molecular Signature Detection with Multi-Modal Microscopy Scanner (M3S)
Date du début: 1 janv. 2014, Date de fin: 31 déc. 2016 PROJET  TERMINÉ 

For many diseases, diagnosis through morphological studies at microscopic scale is the first step conducting to deeper investigations. Yet current tools barely benefit from new biophotonics technologies that could facilitate and greatly improve both early diagnosis and referral to personalized treatments. Associated to an automation of data collection and analysis, such solutions could constitute powerful instruments for better care of patients.M3S thus intends to gather complementary options developed independently by partners and now reaching the maturity to be integrated and evaluated in routine care clinical settings. Once combined, they will efficiently answer the clinical needs and provide a more comprehensive alternative to existing approaches. The final global platform will include three major components:1) An innovative biophotonics-based imaging instrument associating a Raman micro-spectrometer and an accurate stage controller to scan unstained samples and acquire spectral signatures of representative cell or cell compartment2) A powerful image workstation localizing and identifying objects of interest and capturing exploitable data3) A new and efficient data extractor and analyzer based on the Q Finder® algorithm detecting and characterizing molecular signatures through exhaustive exploration of multivariate dataThe approach aims to i) limit the use of markers and dyes whose preparation is difficult to standardize, ii) identify new intrinsic physico-chemical markers specific for a given pathology and iii) detect local configurations where risks or opportunities have shown to be significantly higher or lower than average, allowing a more sensitive diagnosis and a more secure and adapted selection of treatments.Although the developed technologies can be applied in various situations, the efficiency of the integrated solution will be tested in two pathologies for which previous information have been collected: Chronic Lymphocytic Leukaemia and malaria.



10 Participants partenaires